Oceanpine Capital is a professional investment management firm dedicated to long-term investment with a focus on value creation.
Business Model:
Revenue: $0
Employees: 0-0
Address: 1 Garden Road
City: Central
State: hong kong special administrative region
Zip: 999077
Country: CN
Oceanpine Capital is a professional investment management firm dedicated to long-term investment with a focus on value creation. We provide long-term capital and professional value-added services to high-growth enterprises and start-up companies. Oceanpine Capital is headquartered in Hong Kong with offices in Beijing and San Francisco. We focus on investment opportunities in the TMT, consumption upgrade, advanced manufacturing, and healthcare sectors. We mainly invest in private companies with rapid growth, but also look at some opportunities in public companies. Our professional team consists of entrepreneurs, investment professionals, investment bankers and company executives with proven track records. As a team, we stand out in terms of providing strategic resources support and professional value-added services to our investee companies along with our capital.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
3/2021 | JuLive.com | Series C | 61.6M |
6/2019 | Enflame | Series A | 0 |
5/2020 | Enflame | Series B | 98.8M |
5/2021 | Weilong Foods | Series A | 558M |
3/2022 | Shenzhen Shifeng | Series A | 0 |
6/2021 | Tongshu Gene | Series C | 78.1M |
4/2021 | TechnoDerma Medicines | Series A | - |
2/2019 | Horizon Robotics | Series B | 0 |
12/2021 | OrthoGuard | Series A | - |
11/2022 | SIRUI | Venture Round | - |
9/2020 | XtalPi | Series C | 318.8M |
12/2021 | Chipone Technology | Series E | 0 |
9/2021 | MingMed | Series A | 0 |
8/2021 | Svolt Energy Technology Co., Ltd. | Series B | 0 |
8/2020 | Sinovent | Series C | 144.7M |
7/2018 | Tiger Brokers | Series C | 80M |
9/2022 | Qinghai Lihao | Series B | 306.5M |
2/2021 | Clover Biopharmaceuticals | Series C | 230M |
8/2020 | HireEZ | Series B | 13M |
8/2022 | Enflame | Series C | - |
8/2018 | 51zhaoyou.com | Series C | 150M |
12/2021 | Yuchuang Semiconductor | Series A | 15.7M |
9/2020 | Creative Biosciences | Series C | 87.9M |
8/2020 | Triumvira Immunologics | Series A | 0 |
2/2021 | Teon Therapeutics | Series A | 0 |
5/2022 | Aqronos | Series A | - |
10/2019 | Ansun BioPharma | Series B | 100M |
3/2020 | Apexigen | Series C | 65M |
5/2018 | Ansun BioPharma | Series A | 85M |
3/2021 | Immune-Onc Therapeutics | Series B | 0 |
2/2021 | Yisheng Biopharma | Series B | 0 |
1/2023 | Kuixin Technology | Series A | 14.8M |
2/2022 | Clounix | Series A | 0 |
2/2022 | Lianshu Technology | Angel Round | 0 |
5/2022 | Aqronos | Series A | - |
3/2022 | Shenzhen Shifeng | Series A | 0 |
2/2022 | Clounix | Series A | 0 |
2/2022 | Lianshu Technology | Angel Round | 0 |
12/2021 | OrthoGuard | Series A | - |
12/2021 | Yuchuang Semiconductor | Series A | 0 |
12/2021 | Chipone Technology | Series E | 0 |
9/2021 | MingMed | Series A | 0 |
8/2021 | Svolt Energy Technology Co. | Series B | 0 |
6/2021 | Tongshu Gene | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|